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1. Introduction 
The term venous thromboembolism (VTE) covers both the deep vein thrombosis (DVT) 
(where blood clots inappropriately in the deep veins), and its potentially lethal 
consequence – the pulmonary embolism (PE) (where a clot breaks free and travels into 
the pulmonary arteries) (1). VTE is a major health concern, as it is estimated to affect 
up to 5% of people during their lifetimes (2), and 1-2 people out of a thousand 
annually (3). 
Even though currently many of the risk factors have been identified (table 1), a 
significant portion of the cases are idiopathic. Approximately 50% of the patients have 
no identifiable acquired risk factors, and around 10%-20% of the patients have no 
distinguishable acquired or genetic risk factors. This shows us VTEs etiology is not yet 
fully understood. (1) 
 
GENETIC ACQUIRED TRANSIENT ACQUIRED 
Family history Advanced age Pregnancy 
Factor V Leiden Antiphospholipid antibodies Oral contraceptives 
Prothrombin G20210A Cancer Hormone therapy 
Protein C deficiency Chronic disease Hospitalization 
Protein S deficiency Obesity Surgery 
Antithrombin deficiency  Trauma 
Sickle cell trait  Immobilization 
Table 1. Risk factors for venous thromboembolisms (1)  
 
 
 
 
 
2 
 
1.1. Diagnostic Process 
The diagnosis of a DVT is usually based on the anamnesis, clinical examinations, 
laboratory results and a Doppler ultrasound. Symptoms include swelling, pain, warmth, 
redness, fever and walking-related tenderness. Nevertheless, many of the VTEs are un-
symptomatic, and roughly 10% are hence incidental findings. (3) 
Symptoms often occurring with PE include tachypnea, shortness of breath, a pleural 
rub, pleuritic chest pain, hypoxia, hemoptysis, tachycardia, syncope together with 
accompanying symptoms, DVT symptoms and right heart failure. PE can be diagnosed 
using a ventilation/perfusion scan or, nowadays predominantly, a spiral computed 
tomography scan. (3,4) If PE causes right ventricular strain it may be seen through 
elevated levels of P-ProBNP and P-TNT in the blood samples (3).  
The D-dimer is a predictive tool, used to exclude a VTE in cases with a small or 
moderate clinical probability (3) (appendices 2 and 3). However, the D-dimer can be 
elevated for multiple reasons unrelated to VTE (5). 
The simplified pulmonary embolism severity index (sPESI) (appendix 1) is a tool 
designed to help predict a 30-day outcome for PE patients. Those with a sPESI 
outcome of 0 are considered to be low-risk patients and could be considered for early 
discharge and outpatient treatment. Approximately a third (13% to 51%) of PE patients 
fit into this category. However, also other factors such as patient compliance and social 
backgrounds must be taken into consideration before discharge. (6) 
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1.2. Anatomic locations 
Most VTEs occur in the lower extremity, which is generally divided into two regions. 
The proximal veins of the lower extremity are the popliteal vein and those cranially 
from it, while consequently those caudally are considered as its distal veins. The soleus 
and gastrocnemius veins are part of the deep distal venous system of the lower 
extremity. (3) 
Isolated distal deep vein thrombosis (IDDVT) is a common manifestation of a VTE, yet it 
remains to be a topic which requires more research. Even though there is an 
insufficient amount of studies focusing on IDDVTs treatment and association with PE, 
they are, nonetheless, known to be related with fewer recurrences than other VTEs. 
Alongside with IDDVTs, another question of interest is whether or not isolated calf 
muscle veins (ICMV) should actually be categorized as deep veins – therefore leading 
to uncertainty concerning their treatment. (7) 
Somewhat 4% of the DVTs occur in the upper extremity, where the thrombus can be 
classified as primary or secondary. Secondary thrombi are results of central venous 
catheters, pacemakers or cancer, and they represent 75% to 80 % of the cases. Effort-
induced thrombosis is most common in males under the age of 45. (8) 
In addition, thrombotic events can occur in other unusual sites. Even though these 
locations are less frequent, they are often more challenging due to the severe 
outcomes and lack of clinical trials. Cerebral vein thrombosis often affects young 
females, with headache being the most common symptom. (9) Portal vein thrombosis 
can occur in both childhood and adulthood (10), with abdominal pain as the most 
frequent syndrome. (9) 
The most significant superficial veins of the lower extremity include the great and 
small saphenous vein. The former travels from the medial ankle anteromedially 
through the calf up into the thigh and joins the common femoral vein at the 
saphenofemoral junction. The latter travels from the lateral foot to the posterior side 
of the lateral malleolus, continues posteriorily through the calf into the popliteal vein 
through the saphenopopliteal junction at the popliteal fossa. Variations in the anatomy 
occur amongst patients. (11) 
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1.3. Association between cancer and VTE 
Studies show that patients with active cancer have somewhere between a four to eight 
times greater risk of developing a VTE than those who are cancer-free (5,12-15). Even 
though the exact risk cannot be precisely estimated, it is clearly a significant issue, as 
approximately 20% to 30% of the primary VTEs occur in cancer patients (12,14,16). 
Cancer patients with VTEs have twice the mortality rate of cancer patients without 
VTEs (14), and currently VTEs are the second leading cause of death in cancer patients 
– coming second to only cancer itself (12,16).  Thrombotic events are most likely to 
occur during the initial three months following the cancer diagnosis. The risk remains 
rather high until the 12th month, and decreases to almost no elevated risk only after 10 
years (12). 
Although different studies have slight variations when it comes to which cancer types 
have the highest association with VTEs, some malignancies appear to repeatedly stay 
on top of the list. At least lung cancer, gastrointestinal cancer and hematological 
malignancies have been accepted as cancers with high risks of VTEs rather 
unanimously (12,13,17). In addition the following are mentioned: brain, ovarian, and 
kidney cancer (12,17).  
Especially metastasized cancers seem to be associated with a higher risk of a VTE (13), 
as approximately half of those patients with cancer during the diagnosis of a VTE also 
have metastases (14). When it comes to the location of the thrombus, cancer has been 
associated with arm or intra-abdominal DVTs, but not with PEs (14).  
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1.3.1. Cancer-related challenges 
Cancer patients have not only a greater incidence of thrombotic events, but also a 
higher risk of developing anticoagulation-related bleeding problems. Therefore 
thromboprophylaxis isn’t recommended unless the patient has such a high risk of a 
VTE, that it surpasses the risk of bleeding.(12) 
Cancer patients possess more than twice the risk of developing recurrent venous 
thromboembolic events despite the use of adequate doses of low molecular weight 
heparin (LMWH), than non-oncologic patients receiving anticoagulation therapy 
(LMWH followed by warfarin). If cancer patients are treated with vitamin K antagonists 
(VKA), there are often problems with keeping the international normalized ratio (INR) 
within the therapeutic range. (5) 
In addition to the challenges mentioned above, cancer patients are a difficult group to 
treat due to multiple other issues such as chemotherapy, hormonal agents, invasive 
procedures, long-term central venous catheterization and short life expectancy (18) – 
the one year survival rate being only circa 40% (3).  
 
 
1.4. Treatment 
The duration of the anticoagulation treatment can be divided into three subcategories. 
The acute treatment counts for the first 5-10 days. Following this comes the long-term 
treatment lasting up until 3-6 months, and treatment after this is called extended. (15)  
Generally VTE patients are treated for 3 months with one of the following options: 
LMWH, VKA, novel oral anticoagulants (NOAC) or fondaparinux (table 2). As there are 
multiple options regarding the choice of anticoagulants, the used treatment should be 
based on risk, benefit, etiology, cost and patient preference. (2) 
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ANTICOAGULANT ACTIVE INGREDIENT STRENGTHS WEAKNESSES SOURCE 
Vitamin K 
antagonist (VKA) Warfarin 
-Taken orally 
-Inexpensive 
-Requires regular 
INR monitoring 
-Fluctuating INR 
levels can result 
in recurrent 
thrombosis or 
excessive 
bleeding 
-Must be stopped 
days before 
invasive 
procedures 
(18) 
Low molecular 
weight heparins 
(LMWH) 
Dalteparin 
Enoxaparin 
Tinzaparin 
-Routine 
monitoring not 
required 
-Rapid onset of 
action 
-Outpatient 
treatment is safe 
-Subcutaneous 
injections may 
cause discomfort 
(18) 
Novel oral 
anticoagulants 
(NOAC) 
Dabigatran 
Apixaban 
Rivaroxaban 
-Taken orally 
- Routine 
monitoring not 
required 
-Unpredictable 
absorption and 
drug interaction 
-Lack of an 
antidote 
(apixaban and 
rivaroxaban) 
-Higher risk of GI-
bleeding 
(17) 
Others Fondaparinux 
-Routine 
monitoring not 
necessary 
-Low risk for 
heparin induced 
thrombocytopenia 
(HIT) 
-Subcutaneous 
injections may 
cause discomfort 
(19) 
Table 2. Most frequently used anticoagulants  
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The duration of treatment should be decided based on several individual factors, such 
as previous VTEs, risk factors (Table 1), location, magnitude, bleeding risk, and patient 
compliance (3). The decision to continue extended treatment is based on evaluating 
the etiology of the VTE, the risk of recurrent VTEs and the risk of major bleeding (2). 
Anticoagulation is often used for indefinitely when there is an irremovable risk factor 
for the time being. Permanent treatment is preferred for patients with a genetic risk 
factor for VTE (table 1) already after the first thrombus. It is also used for patients with 
repeating idiopathic DVTs. (3) 
It is common policy in Finland to treat IDDVTs with anticoagulation, even though this 
approach varies internationally (3). Most guidelines recommend a three month 
anticoagulation period, even though 6 weeks could be just as effective (7). 
Studies show that recurrence amongst untreated IDDVTs is rare – suggesting that their 
anticoagulation treatment may be unnecessary. (7) However, according to the Käypä 
hoito -recommendation (3) anticoagulation treatment should be used at least if the 
IDDVT is symptomatic, or if the patient has significant risk factors (Table 1). 
Upper extremity DVTs are treated in the same manner as lower extremity DVTs (3) as 
especially veins from the axillary vein proximally are associated with a high risk of PE 
(2). PEs have been reported in anywhere between 0% to 36% of patients with upper 
extremity DVTs (9). 
 
 
1.4.1. Treatment of cancer-related VTEs 
The Cochrane study (20) shows that cancer-related long-term anticoagulation with 
LMWH significantly reduces the risk of VTE recurrence when compared to treatment 
with warfarin. In addition, LMWH treatment doesn’t increase the amount of bleeding 
complications or affect the mortality rate. Be that as it may, it appears that LMWH 
doesn’t significantly reduce recurrent VTEs in patients without cancer for reasons yet 
unclear. (20)  
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Although it isn’t fully understood why LMWH is superior to warfarin in the 
anticoagulation treatment of cancer patients, it has been suggested that they are less 
responsive to warfarin treatment (instead of reacting better to LMWH treatment) 
(18,21). Some studies propose that LMWH could actually inhibit angiogenesis, and in 
that manner restrict tumor growth and metastasis. This claim is supported by evidence 
that the use of dalteparin (compared to oral anticoagulants) reduces the risk of 12-
month mortality in cancer patients with solid tumors, if they weren’t known to have 
metastases. (22) 
Even though NOACs and warfarin are efficient in treating VTEs unrelated to cancer, 
LMWH is recommended for both the acute and the long-term treatment for patients 
with malignancies (in the absence of contraindications). (5,17,23) 
 
 
1.4.2. Cancer and duration of treatment 
The duration of anticoagulation should be at least 3-6 months for patients with active 
cancer, and extended treatment should be considered (5,15-17). Whether the optimal 
treatment period is 3 or 6 months remains uncertain, as so far no study has compared 
these two (16). Patients with active cancer include, inter alia, those with metastatic 
disease and those with ongoing chemotherapy (4).  
According to the Cancer-DACUS Study (23), the lack of a residual vein thrombosis (RVT) 
after a six-month anticoagulation period with LMWH indicates a low risk for recurrent 
thrombotic events. This calls in question the practicality of extended treatment, as it is 
a burden economically, may cause discomfort, and increases the risk of bleeding 
(16,23). 
Extended treatment reduces the risk of recurrent thromboembolisms as the 
anticoagulation is ongoing. However, the risk increases as soon as the therapy ends, 
and returns to the same level as without extended treatment after two years. (5) This 
shows us, that prolonging the treatment doesn’t seem to produce long-term benefits.  
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Even though extended treatment is often practiced for patients with active cancer, this 
protocol is not based on randomized trials (4,23), and the topic requires further 
research and clinical trials. The extended treatment can be performed by LMWH or 
warfarin (3). 
It is safe to say, that currently extended treatment should be decided on a case-by-
case basis, considering the benefits, risks, tolerability, patient preference and cancer 
activity (16). As cancer patients differ in their types, stages and histologies of the 
cancer, generalization of the required treatment is near impossible (23). 
 
 
1.4.3. Cancer screening in idiopathic VTE 
It is not uncommon to find an underlying malignancy after the diagnosis of an 
idiopathic VTE. As studies suggest, up to 10% of these patients are diagnosed with 
cancer in the following year, and over 60% of occult cancers are diagnosed as a result 
of unprovoked VTEs. (24) This ought to be kept in mind as dealing with first 
unprovoked VTEs. Screening can be performed through history taking, basic blood 
testing, physical examinations, chest radiography and age- and sex-specific screening. 
Nonetheless, it is not recommended to perform extensive screening (including CT 
[computed tomography]) for occult cancers without symptoms pointing at it, as it 
doesn’t appear to reduce cancer-related mortality. (5) 
 
1.5. Thrombolysis 
Thrombolysis can be used in a high-risk pulmonary embolism, or in a DVT extending 
above the inguinal ligament with prominent symptoms and signs. The criteria for use 
of thrombolysis related to the upper extremity are similar. The bleeding risk 
accompanying thrombolysis must always be taken into consideration. (3) There is, 
however, no evidence of thrombolysis reducing the rate of VTE-recurrence, PE, or 
mortality (2). 
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1.6. Superficial thrombophlebitides 
Superficial thrombophlebitis (STP) is an inflammatory process, often associated with 
blood clots affecting the superficial veins. Symptoms include localized pain, 
tenderness, itching, redness of the skin, and hardening of the neighboring tissue (25) 
Studies suggest there is an association between STP and VTE. It has been estimated, 
that STP’s incidence is higher than DVT’s. (25) Of the STPs extending to the length of 
over 5cm, over 20% progress into a DVT (3) and both DVT and PE are their possible 
complications (26). As there isn’t research concerning the incidence of STPs in cancer 
patients, it is yet unclear should it be interpreted as a possible sign of occult cancer 
(12). 
There is limited evidence regarding the treatment of STPs. Fondaparinux has been 
recorded to be associated with a significantly reduced amount of symptomatic VTEs, 
STP-extension and recurrent STPs without increasing bleeding relative to placebo. Also 
LMWHs and NSAIDs have been demonstrated to reduce extension and recurrence of 
STPs, however, without significant effect on symptomatic VTEs. (25) Currently, 
recommendations suggest the use of LMWH for the minimum of one month in the 
treatment of STPs (26).  
 
1.7. Bleeding 
Before the development of adequate anticoagulants, untreated VTEs were fatal in 
approximately 30% of cases. Despite offering better starting points for treatment 
nowadays, they do not come risk-free: anticoagulation therapy increases the risk of 
major bleeding – being fatal in up to 25% of cases. (2) 
The highest risk of bleeding in cancer patients is during the first month. If treatment is 
extended beyond six months, months 6 to 12 have similar rates of recurrence and 
bleeding as months 2 to 6. (15) The reported rates of severe bleeding are 2% - 5% with 
warfarin, 1,2% with LMWHs and 3%-6% with NOACs (3). 
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2. Aims 
The primary aim of this study was to find out whether venous thromboembolism is 
treated according to the current recommendations in the HDHU-area. Patients without 
active cancer were included as controls.  The complete list of aims was:  
 
1. to find out the choice of anticoagulant and the planned duration of the 
anticoagulation in cancer patients and control. 
2. to find out the frequency of different locations of thrombotic events, in order 
to see if cancer patients were more prone to certain types of thrombi. 
3. to assess the prevalence of bleeding complications due to anticoagulation.  
4. to describe the characteristics of the patients, and to analyze the associations 
between VTEs and age, sex, and malignancies.  
5. to analyze the duration from cancer diagnosis to VTE discovery 
6. to evaluate the possibility for home treatment of PE in control group by 
calculating the sPESI-score. 
7.  to analyze the 6-month mortality-rate. 
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3. Materials and methods 
 
3.1. Materials 
Data was collected from patient records in the Oberon software. All patient records 
(with the diagnostic codes I26.0 pulmonary embolism with acute cor pulmonale, I67.6 
nonpyogenic thrombosis of intracranial venous system, I74.3 embolism and 
thrombosis of arteries of the lower extremities, I80* phlebitis and thrombophlebitis, 
I81* portal vein thrombosis, I83* varicose veins of lower extremities, K55 vascular 
disorders of intestine, N28.0 ischemia and infarction of kidney, 022.3 anthrax 
septicemia) in the hospital district of Helsinki and Uusimaa (Jorvi, Meilahti, Peijas, 
Lohja, Porvoo, Tammisaari, Hyvinkää hospitals) during the time period 1.1.2014- 
29.4.2016 were reviewed.  
The original registry included 2833 patients. In the present study, only patients with a 
VTE or STP (in any given location) were included. Patients with a VTE/STP –suspicion 
which was, after further examination, confirmed wrong were excluded. Each patient 
was only analyzed once per VTE/STP.  After this 1667 patients were left suitable for the 
study.  
Excel was used for collecting the required data of the patients. The patients’ gender, 
age, duration of treatment and choices regarding hospitalization versus outpatient 
treatment were reviewed. If the patient has passed away, time and cause of death 
were searched as far as it was possible.  
It was planned to find out how many of the pulmonary embolism patients could have 
been suitable for outpatient management, and hence information required for the 
sPESI-evaluation (appendix 1) was collected. 
Regarding the patients with active or previous cancer, data was collected about the 
type of the cancer, whether or not it has metastasized, and when it has been 
diagnosed. The practiced cancer treatment during the time of the VTE/STP was also 
recorded. According to the treatment, the cancer was classified as active or non-active 
in the following manner:  
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NON-ACTIVE CANCER ACTIVE CANCER 
Recovered Active care 
In partial remission Palliative care 
In complete remission 
Recently discovered malignancy (care 
hasn’t started yet) 
 
Patient has cancer but refuses further 
research/treatment 
 End-of-life care 
Table 3. Classification of active cancer  
 
Information was collected on the location of the VTE/STP and whether it was a primary 
symptom or an incidental finding. Were the patient to have a pulmonary embolism, 
reports were checked to see was there right ventricular strain or an embolism within 
the heart.  
The choices of anticoagulants regarding the used long-term and extended treatment 
were collected, while also tracking the durations of the medication. Previous VTEs or 
genetic factors contributing to the prolongation of the prescribed treatment were also 
marked down. Finally, hemorrhages due to the anticoagulation treatment were 
searched.  Only the cases with sufficient information have been included in the tables.  
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3.2. Methods 
Statistical analysis was performed using the IBM SPSS Statistics and Microsoft Excel 
computer softwares.  The Chi-Square test was used for data analysis with 0.05 
probability level as the critical value. 
Often patients had thrombi in multiple locations. Since the results would have been 
hard to interpret if every single VTE and STP were to have been listed separately in 
each case, locations were classified in the following manner (Figure 1): 
First, patients with either a portal vein (and possibly mesenteric vein) thrombosis or 
cerebral vein sinus (and possibly jugular and/or cortical vein) thrombosis were divided 
into their own categories.  
Next, categories were formed of the thrombi affecting the pulmonary arteries and 
limbs in the hierarchical manner described above, favouring always those closest to 
the heart. This way no thrombus was counted twice, and the result could be analysed 
and presented in a comprehensible manner. The aim was to have the choice of 
treatment reflect the location of the thrombus as precisely as possible.  
After this 16 thrombi were left, not fitting into the categories above. The locations of 
these mainly included veins of the neck (jugular veins) and the abdominal region 
(mesenteric veins, splenic vein). In addition, thrombi were identified in the ovarian 
vein, the brachiocephalic vein and the inferior and superior vena cava. These were all 
grouped in to the “others” category.  
The classification “permanent treatment” applies to cases, where treatment is planned 
to be continued permanently, if no contraindications appear. The classification 
“indefinite treatment” applies to cases, where the duration of the treatment hasn’t yet 
been decided. Often these patients had transient acquired risk factors (table 1), during 
which anticoagulation was planned to be continued.   
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Figure 1. Classification of anatomical location of venous thromboembolisms and 
superficial thrombophlebitides 
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3.3. Limitations 
The data was based completely on the clinical information system database Uranus 
CGI. Many of the entries were incomplete due to the lack of their content regarding 
the recorded variables, or written in a manner that couldn’t be interpreted in and 
adequately unequivocal way. The content of such data was therefore incomplete. Only 
patients with sufficient treatment-related information are included in the results-
section. 
Other possible reasons for the durations of the hospitalization and anticoagulation 
could not be excluded. Patients could have an extended time spent in the ward due to 
diseases unrelated to the VTE/STP, and medication could last for longer than expected 
because of other underlying conditions (e.g. atrial fibrillation).  
Too many assumptions regarding whether or not the treatments are appropriate 
cannot be made, as we have not collected all the background information leading to 
these decisions. These could include factors such as contraindications, underlying 
diseases, patient preferences and co-operation.   
One of the original aims was to find out the percentage of patients who suffered from 
severe bleeding complications due to each group of anticoagulants. Due to the vast 
number of patients treated with combinations of different anticoagulants, this became 
impossible to accurately describe.   
We had no access to the official death certificates, and the information related to the 
causes of death was limited. 
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4. Results 
 
After excluding the patients unrelated to our study, 1667 patients from ages 16 to 102 
(mean 59.0, SD 16.9) were left, out of whom 760 (45.6%) were male and 907 (54.4%) 
female (table 4). There were 28 incidental VTE-findings (1.7%) in the whole group, out 
of which 11 appeared in cancer patients (p < 0.001). In other words, 6.7% of the 
thrombotic events in cancer patients were incidental findings. 15 new malignancies 
were found in the courses of the VTE treatment periods. Out of the 163 patients with 
active cancer, 90 (55.2%) had metastases. 
 VTE* (n=1185) STP** (n = 482) 
Male 583 (49.2 %) 177 (36.7 %) 
Female 602 (50.8 %) 305 (63.3 %) 
Table 4. Frequencies of VTEs and STPs 
* VTE = venous thromboembolism  
** STP = superficial thrombophlebitis 
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The following tables represent the choices in treatment in relation to the thrombus’s 
location. 
Location of 
thrombosis All patients  
Patients 
without 
active cancer  
Patients 
with active 
cancer  
P-value 
Pulmonary 
embolism 204 (17.2 %) 175 (16.6 %) 29 (22.0 %) 0.023 
Lower extremity, 
proximal 388 (32.7 %) 349 (33.1 %) 39 (29.5 %) 0.836 
Lower 
extremity, 
distal 
Calf 
muscle 127 (10.7 %) 117 (11.1 %) 10 (7.6 %) 0.639 
Other 275 (23.2%) 257 (24.4 %) 18 (13.6 %) 0.048 
Above inguinal 
ligament 95 (8.0 %) 75 (7.1 %) 20 (15.2 %) < 0.001 
Upper extremity, 
proximal 12 (1.0 %) 9 (0.9 %) 3 (2.3 %) 0.075 
Upper extremity, 
distal 3 (0.3 %) 3 (0.3 %) 0 (0.0 %) 0.568 
Subclavia 18 (1.5 %) 17 (1.6 %) 1 (7.6 %) 0.544 
Portal vein 21 (1.8 %) 18 (1.7 %) 3 (2.3 %) 0.484 
Cerebral sinus 27 (2.3 %) 24 (2.3 %) 3 (2.3 %) 0.814 
Other 15 (1.3 %) 9 (0.9 %) 6 (4.5 %) < 0.001 
All 1185 (100.0%) 
1053 
(100.0%) 
132 
(100.0%) - 
 
 
 
 
 
 
 
Table 5. Locations of deep venous thromboembolisms  
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Location of 
thrombosis All patients  
Patients without 
active cancer  
Patients with 
active cancer  P-value 
Thrombophlebitis 482 (100.0 %) 451 (93.6 %)  31 (6.4 %)  0.023 
Table 6. Amount of thrombophlebitides 
 
 
 
 
Table 7. Anticoagulant choices of thrombi in portal veins, cerebral sinuses and other 
locations 
Duration of treatment (months) 
Portal vein/Cerebral 
sinus/Other, no cancer 
(n=45) 
Portal vein/Cerebral 
sinus/Other, cancer 
(n=11) 
<3 1  (2.2 %) - 
3 4 (8.9 %) - 
3-6 1  (2.2 %)  1 (9.1 %) 
6 27 (60.0 %) 4 (36.4 %) 
6-12 1  (2.2 %)  - 
12 1  (2.2 %)  - 
>12 1  (2.2 %)  - 
permanently 4 (8.9 %) 3 (27.3 %) 
indefinitely 5 (11.1 %) 3 (27.3 %) 
Table 8. Duration of portal vein, cerebral sinus and other thrombi’s anticoagulation 
Anticoagulant 
Portal vein/Cerebral 
sinus/Other, no cancer 
(n=50) 
Portal vein/Cerebral 
sinus/Other, cancer (n=12) 
Warfarin 19 (38.0 %) - 
LMWH 22 (44.0 %) 12 (100.0 %) 
NOAC 2 (4.0 %) - 
combination of anticoagulants 7 (14.0 %) - 
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Anticoagulant 
Above 
inguinal 
ligament, 
no cancer 
(n=74) 
 
Above 
inguinal 
ligament, 
cancer 
(n=20) 
Lower 
extremity, 
proximal, 
no cancer 
(n=348) 
Lower 
extremity, 
proximal, 
cancer 
(n=37) 
PE*, no 
cancer 
(n=174) 
 
PE*, 
cancer 
(n=29) 
 
Warfarin 44      (59.5 %) - 
172   
    (49.4 %) 
6       
    (16.2 %) 
88   
 (50.6 %) - 
LMWH** 20       (27.0 %)  
16     
 (80.0 %) 
55     
    (15.8 %)  
27         
(73.0 %) 
31   
 (17.8 %)  
27      
(93.1 %) 
NOAC*** 8         (10.8 %) - 
101  
     (29.0 %)  - 
49 
 (28.2 %)  - 
fondaparinux - 1 (5.0 %) - 2 (5.4 %) 3 (1.7 %) - 
combination 
of 
anticoagulants 
2 
  (2.7 %) 
3        
(15.0 %) 
20  
(5.7 %)  
2 
 (5.4 %) 
3 
 (1.7 %) 
2 
 (6.9 %) 
 
Table 9. Anticoagulant choices of thrombi above the inguinal ligament, in the proximal 
lower extremity and pulmonary embolisms 
* pulmonary embolism 
** low-molecular-weight heparin 
*** novel oral anticoagulant 
Duration of 
treatment 
(months) 
Above 
inguinal 
ligament, 
no cancer 
(n=67) 
 
Above 
inguinal 
ligament, 
cancer 
(n=17)   
Lower 
extremity, 
proximal, 
no cancer 
(n=333)  
Lower 
extremity, 
proximal, 
cancer 
(n=34) 
 
PE, no 
cancer 
(n=165) 
 
PE, cancer 
(n=27) 
 
<3 1 (1.5 %) - 6 (1.8 %) 1 (2.9 %) 4(2.4 %) - 
3 3  (4.5 %) - 
44  
(13.2 %) 
4 
 (11.8 %) 
8 
 (4.8 %) - 
3-6 2 (3.0 %) - 6 (1.8 %) - 1 (0.6 %) - 
6 28  (41.8 %) 
4  
(23.5 %) 
150 
 (45.0 %) 
9  
(26.5 %) 
75 
 (45.5 %) 
10 
 (37.0 %) 
6-12 1 (1.5 %) -  1 (2.9 %) 1 (0.6 %) - 
12 2  (3.0 %) 
1 
 (5.9 %) 
4 
 (1.2 %) 
1 
 (2.9 %) 
6 
 (3.6 %) 
3  
(11.1 %) 
>12 - - - - 2 (1.2 %) - 
permanent
ly 
16 
 (23.9 %) 
9 
 (52.9 %) 
82 
 (24.6 %) 
11  
(32.4 %) 
48  
(29.1 %) 
5 
 (18.5 %) 
indefinitely 14 (20.9 %) 
3 
(17.6 %) 
41 
(12.3 %) 
7 
(20.6 %) 
20 
(12.1 %) 
9 
(33.3 %) 
Table 10. Duration of anticoagulation of thrombi above the inguinal ligament, in the 
proximal lower extremity and pulmonary embolisms 
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Anticoagulant 
Subclavia, no 
cancer (n=17) 
 
Subclavia, 
cancer (n=1) 
Upper 
extremity, no 
cancer (n=12) 
Upper extremity, 
cancer (n=3) 
Warfarin 9 (52.9 %) - 9 (75.0 %) - 
LMWH 3 (17.6 %) 1 (100.0 %) 3 (25.0 %) 2 (66.7 %) 
NOAC 5 (29.4 %) - - - 
combination of 
anticoagulants - - - 1 (33.3 %) 
Table 11. Anticoagulant choices of thrombi in the subclavian vein and upper extremity 
Duration of 
treatment 
(months) 
Subclavia, no 
cancer (n=14) 
 
Subclavia, 
cancer (n=1) 
Upper 
extremity, no 
cancer (n=11) 
Upper extremity, 
cancer (n=3) 
<3 - - 1 (9.1 %) - 
3 5 (35.7 %) - 1 (9.1 %)  1 (33.3 %) 
6 7 (50.0 %) 1 (100.0 %) 1 (9.1 %)  - 
12 1 (7.1 %) - 1 (9.1 %)  - 
permanently 1 (7.1 %) - 3 (27.3 %) 1 (33.3 %) 
indefinitely  - 4 (36.4 %) 1 (33.3 %) 
Table 12.  Duration of anticoagulation of thrombi in the subclavian vein and upper 
extremity 
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Anticoagulant 
Lower extremity, 
distal no cancer 
 
Lower extremity, 
distal, cancer STP**, no 
cancer 
(n=352) 
STP**, 
cancer 
(n=25) ICMV* 
(n=110) 
other 
(n=257) 
ICMV* 
(n=10) 
other 
(n=18) 
Warfarin 26  (23.6 %) 
125 
(48.6 %) 
2 
(20.0 %) 
1 
(5.6 %) 
20 
(5.7 %) - 
LMWH 43 (39.1 %) 
27 
(10.5 %) 
5 
(50.0 %) 
15 
(83.3 %) 
312 
(88.6 %) 
25 
(100.0 %) 
NOAC 40 (36.4 %) 
98 
(38.1 %) 
2 
(20.0 %) - 
13 
(3.7 %)  
fondaparinux - - - - 2 (0.6 %) - 
combination of 
anticoagulants 
1  
(0.9 %) 
7 
(2.7 %) 
1 
(10.0 %) 
2 
(11.1 %) 
5 
(1.4 %) - 
Table 13. Anticoagulant choices of thrombi in the distal lower extremity and STP 
* Isolated calf muscle vein 
** Superficial thrombophlebitis 
Table 14. Duration of anticoagulation of thrombi in the distal lower extremity and STP 
Duration of 
treatment 
(months) 
Lower extremity, distal 
no cancer 
 
Lower extremity, distal, 
cancer STP, no 
cancer 
(n=349) 
STP, cancer 
(n=24) 
ICMV 
(n=107) 
other 
(n=251) 
ICMV 
(n=11) 
other 
(n=18) 
<3 36  (33.6 %) 
5 
 (2.0 %) 
2  
(18.2 %) - 
292  
(83.7 %) 
16 
 (66.7 %) 
3 41  (38.3 %) 
86 
 (34.3 %) 
4 
 (36.4 %) 
2 
 (11.1 %) 
12 
 (3.4 %) 
2 
 (8.3 %) 
3-6 3  (2.8 %) 
12  
(4.8 %) 
1 
 (9.1 %) - 
3  
(0.9 %) 
2 
 (8.3 %) 
6 12  (11.2 %) 
83 
 (33.1 %) 
2  
(18.2 %) 
5  
(27.8 %) 
10 
 (2.9 %) - 
6-12 - 1  (0.4 %) - 
1 
 (5.6 %) - - 
12 - 3  (1.2 %) - - 
1 
 (0.3 %) 
1 
 (4.2 %) 
>12 - - - - 1  (0.3 %) - 
permanently 11  (10.3 %) 
38  
(15.1 %) 
2  
(18.2 %) 
5 
 (27.8 %) 
13 
 (3.7 %) - 
indefinitely 
4  
(3.7 %) 
23  
(9.2 %) 
- 
5  
(27.8 %) 
17 
 (4.9 %) 
3 
 (12.5 %) 
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All in all 100 (20.7 %) of the patients with STPs had either been treated only by topical 
treatments, or then been left untreated. In addition, seven (5.5 %) of the patients with 
ICMV thrombi had been treated only by topical treatments. 
 
Choice of anticoagulant Cancer 
(n=130) 
No cancer 
(n=1039) 
P-value 
LMWH 105 (80.8 %) 205 (19.7 %) < 0.001 
Warfarin 10 (7.7 %) 506 (48.7 %) < 0.001 
NOAC 2 (1.5 %) 303 (29.2 %) < 0.001 
Fondaparinux 3 (2.3 %) 4 (0.4 %) N.A. 
Combination 
of 
anticoagulants 
Initial 3 months LMWH 10 (7.7 %) 16 (1.5 %) N.A. 
Initial 3 months NOAC - 5 (0.5 %) N.A. 
Table 15.  Cancer’s effect on the choice of anticoagulant of VTE-patients 
 
Duration of 
treatment 
(months) 
LMWH 
(n=289) 
NOAC  
(n=299) 
Warfarin 
(n=479) 
Fondaparinux 
(n=5) 
Combination 
of 
anticoagulants 
(n=22) 
<3 46 (15.9 %) 10 (3.3 %) 1 (0.2 %) - - 
3 30 
(10.4 %) 
98 
(32.8 %) 
76 
(15.9 %) 
1 
(20.0 %) 
- 
3-6 5 (1.7 %) 11 (3.7 %) 10 (2.1 %) - - 
6 71 
(24.6 %) 
142 
(47.5 %) 
200 
(41.8 %) 
- 1 
(4.5 %) 
6-12 1 
(0.3 %) 
- 4 
(0.8 %) 
- 1 
(4.5 %) 
12 4 
(1.4 %) 
7 
(2.3 %) 
11 
(2.3 %) 
- 1 
(4.5 %) 
permanently 49 
(17.0 %) 
26 
(8.7 %) 
131 
(27.3 %) 
3 
(60.0 %) 
18 
(81.8 %) 
indefinitely 83 
(28.7 %) 
5 
(1.7 %) 
46 
(9.6 %) 
1 
(20.0 %) 
1 
(4.5 %) 
Table 16. Durations of VTE-treatment according to anticoagulant 
24 
 
 
Anticoagulant Enoxaparin Tinzaparin Dalteparin Warfarin 
Bleeding cases 
(n=11) 
3 3 1 4 
Table 17. Amount of severe anticoagulation-related bleeding complications 
 
There were eleven cases of severe bleeding complications in this study (table 17). 
However, none of them were fatal. All in all the bleeding rate of this study’s patients 
was 0.7 %. 
The patients with histories of malignancies had different cancer types in the following 
proportions:  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Types of cancers in patients with a history of malignancies  
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Figure 4. Types of cancers in patients with active malignancies 
Figure 3. Duration from cancer diagnosis to VTE/STP diagnosis 
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The data included 204 PE patients. Out of them 76 (37.3%) scored a 0 in the sPESI, 106 
(52.0%) got 1 or more points, and from 22 (10.8%) all the necessary information 
required for the sPESI couldn’t be found. In other words, out of those from who all the 
information could be collected 41.8% could have been considered for early discharge.  
Out of the 76 low-risk PE patients 6 were discharged immediately and 5 were 
transferred into another location, from where no further information could be found. 
Therefore, they are not included in the following statistics. 65 patients with clear 
treatment periods were left. Out of them, 24 (36.9%) had a short hospitalization 
duration lasting for only 1-2 days. The range varied from 1 to 31 days, with a mean of 
4.2 days.  
 
 Active cancer 
(n=163) 
No active cancer 
(n= 1504) 
P-value 
6-month mortality  64 (39.3 %) 60 (4.0 %) < 0.001 
Table 18. Six-month mortality-rates after VTE diagnosis 
 
The 6-month mortality rate after VTE/STP diagnosis was 7.4 %. Out of the 124 patients 
who died during this time period, 64 (51.6 %) had active cancer. It appears, that four of 
these patients’ causes of deaths were related to thrombotic events – none of them 
had active cancer. 
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5. Discussion and conclusions 
There were all in all 132 patients with active cancer in this study. The results show that 
recommendations regarding the usage of LMWH as primary anticoagulants have been 
adequately taken into consideration. It seems like patients with malignancies are more 
likely to suffer from VTEs in locations with worse outcomes (pulmonary embolism, 
above inguinal ligament) and less likely to suffer from the more minor clots (distal 
lower extremity, thrombophlebitis).  
The cancer types matched rather well with the previously reported data (12,13,17), as 
cancer patients had high frequencies of gastrointestinal, hematological and lung 
cancers. One difference appears to be the high portion (18.1%) of patients with breast 
cancer in our study. In this study the portion of cancer patients with a metastasized 
cancer was notably high. Previous studies (14) suggest that approximately half of the 
cancer patients with thrombotic events would have metastases – harmonizing well 
with this study’s 55.2%.   
There were 19.3% more females than males suffering from a VTE/STP. The difference 
is mostly do to to STPs. Women had STPs 72.3% more frequently than men, whereas 
VTEs occurred only 3.3% more in females than in males. 
Thrombotic events in the upper extremity occurred amongst 32 (1.9%) of the patients 
– a result which is slightly less than the 4% presented in previous studies (8).   
The results regarding VTE location in cancer patients are somewhat controversial with 
the literature (14). Even though both studies recognized a correlation between cancer 
and VTE in an abnormal location (intra-abdominal/other), the current study 
additionally showed a significant correlation between cancer and pulmonary 
embolism, yet no significant correlation between cancer and DVT of the upper 
extremity. 
A significant amount of thrombotic events occurred within one year of the cancer 
diagnosis being in line with earlier studies (12). This could be partially due to the fact 
that cancer patients have such high mortality rates – without the early deaths more 
VTEs and STPs would most presumably occur also after longer time periods.   (12).  
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Previous studies (2) suggest that major bleeding could be fatal in up to 25% of cases 
(appendix 4). Nonetheless, in this study no case of severe bleeding lead to death.  
The choices in treatment seem adequate, and follow the present guidelines (3). Most 
cancer patients have received LMWH for appropriate time periods.  
However, one unexpected uncertainty that came up in this study was the ICMV –
related treatment. When it comes to the cancer patients, 40.0% percent of them were 
treated by anticoagulants other than LMWHs. Also the durations of the treatments 
vary so notably, that the reason for this is more likely to be inconsistency in treatment 
protocols than sporadic differences between individual patients. There was notable 
variance in regarding  the calf muscle vasculature as either deep or superficial, thereby 
leading to significant diversity in the durations of treatments. Many radiology 
statements referred to the ultrasound findings saying there was no coagulation in the 
deep veins of the low extremity, but some could be found in the veins of the isolated 
calf muscles. This naturally leads to confusion in whether or not the ICMV thrombi 
should be treated in the same manner as other DVTs.  As a result, treatment periods of 
ICMVs ranged from just few weeks up to 6 months (with both cancer and non-cancer 
patients), with no clear majority focusing around any decided duration. In addition, 7 
patients were treated using only topical treatment. 
Another aspect that came up in this study, was the confusion related to the anatomy 
of the superficial femoral vein. Unlike the name may suggest, it belongs to the deep 
venous system of the proximal lower extremity. However, one study (27) suggests that 
75% of clinicians don’t recognize its correct anatomical location or, thereby, realize its 
need for anticoagulation. Treating it as a superficial vein may result in potentially 
unsafe consequences.  
The portion of the non-cancer PE patients scoring 0 from the sPESI fit well in with the 
results of previous studies. As over a third of them were discharged within two days of 
PE diagnosis, it may be concluded that the sPESI results (or otherwise appropriate 
clinical judgment) have been taken into consideration in these cases.  
The six-month mortality-rate of patients without cancer was only 4.0 %. As also 
patients with only STPs were included, it appears rational that the rate is not bigger. 
29 
 
However, the mortality-rate of cancer-patients during the same time period is ten-fold 
higher. Previous studies (3) suggest that cancer-patients have a one-year mortality-
rate of 60% after VTEs. Even though the results of this study cannot be directly 
compared to those, it appears, roughly speaking, that results related to cancer 
patients’ mortality-rates correspond with previous studies.  
 
 
5.1. Conclusions 
Overall, the designated treatments have been adequate, and cases of severe bleeding 
have been rare. In this study, it appears that cancer patients are more likely to suffer 
from thromboembolisms in more severe locations than non-cancer patients.  
Warfarin and LMWHs caused all of this study’s anticoagulation-related severe bleeding 
complications. However, these were by far the most used anticoagulants, making the 
results reasonable.  
What became evident is that further research regarding the optimal treatment of 
ICMV thrombi and cancer patients’ STP is required for the sake of creating a unified 
treatment protocol. Also, physicians ought to be made aware of the anatomical 
location of the superficial femoral vein to in order to avoid potentially harmful 
treatment-related consequences.  
There is still room for improvement in using the sPESI routinely. Embracing it as a 
standard tool could help save time and money, and most importantly improve the 
patients’ qualities of life.  
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List of abbreviations 
VTE – venous thromboembolism 
DVT – deep venous thrombosis 
PE – pulmonary embolism 
IDDVT – isolated distal deep vein thrombosis 
ICMV – isolated calf muscle vein 
STP – superficial thrombophlebitis 
sPESI – simplified pulmonary embolism severity index 
VKA – vitamin K antagonist 
LMWH – low molecular weight heparin 
NOAC – novel oral anticoagulant 
INR – international normalized ratio 
NSAID – nonsteroidal anti-inflammatory drug 
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Appendices 
 
CLINICAL CHARACTERISTIC POINTS* 
Age over 80 years 1 
History of cancer 1 
History of chronic cardiopulmonary 
disease 
1 
Heart rate ≥ 110/min 1 
Systolic blood pressure < 100 mmHh 1 
Oxygen saturation < 90% 1 
Appendix 1. Evaluating the 30-day mortality rate using sPESI (3) 
*Those with a score of 1 or more have a 30-day mortality rate of up to 11% (6)  
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CLINICAL CHARACTERISTIC SCORE* 
Active cancer (treatment ongoing or within previous 6 months or palliative) 1 
Paralysis, paresis or recent plaster immobilization of lower extremity 1 
Recently bedridden for more than three days or major surgery within four 
weeks 
1 
Localized tenderness along the distribution of deep venous system 1 
Entire leg swollen 1 
Calf swelling by more than 3 cm when compared with asymptomatic leg 
(measured 10 cm below tibial tuberosity) 
1 
Pitting oedema (greater in symptomatic leg) 1 
Collateral superficial veins (non-varicose) 1 
Alternative diagnosis as likely or greater than that of deep-vein thrombosis -2 
Appendix 2. Wells model for predicting the clinical pretest probability of deep vein 
thrombosis (28) 
If both legs are symptomatic, the more symptomatic leg is used 
*0 or less = Low risk 
*1 or 2 = Moderate risk 
*3 or more = High risk 
 
 
CLINICAL CHARACTERISTIC SCORE* 
Clinical signs and symptoms of DVT (minimum of leg sweeling and pain with 
palpation of deep veins) 
3 
An alternative diagnosis is less likely than PE 3 
Heart rate greater than 100 1,5 
Immobilization or surgery in previous four weeks 1,5 
Previous DVT/PE 1,5 
Hemoptysis 1 
Malignancy (on treatment, treated in last six months or palliative) 1 
Appendix 3. Wells model for predicting the clinical pretest probability of pulmonary 
embolism (29) 
*< 2 = Low risk 
*2-6 = Moderate risk 
*> 6 = High risk 
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 Fatal bleeding 
n = 135 
Non-fatal major 
bleeding  
n = 411 
Total major 
bleeding 
n = 546 
Gastrointestinal, n 
(%) 
54 (40) 140 (34) 194 (36) 
VTE to major 
bleeding (days)* 
10, 6-25 12, 5-33 12, 5-29 
Major bleeding to 
death (days)* 
1.5, 0-4   
Intracranial, n (%) 34 (25) 37 (9.0) 71 (13) 
VTE to major 
bleeding (days)* 
20, 10-51 32, 7-68 23, 9-54 
Major bleeding to 
death (days)* 
1, 0-2   
Genitourinary, n 
(%) 
7 (5.1) 51 (12) 58 (11) 
VTE to major 
bleeding (days)* 
11, 9-13 20, 4-48 13, 4-44 
Major bleeding to 
death (days)* 
7, 3-13   
Hematoma, n (%) 22 (16) 133 (32) 155 (28) 
VTE to major 
bleeding (days)* 
9, 7-19 10, 4-18 10, 5-18 
Major bleeding to 
death (days)* 
2.5, 1-9   
Other, n (%) 18 (13) 50 (12) 68 (12) 
VTE to major 
bleeding (days)* 
22, 5-43 12, 4-32 12, 3-31 
Major bleeding to 
death (days)* 
1, 0-4   
Appendix 4. Sites and timing of major and fatal bleeding in a study based on findings 
from the RIETE registry (30) 
VTE, venous thromboembolism. Some patients died after repeated episodes of major 
bleeding.  
*Median, interquartile range.  
 
